ASTELLAS PHARMA UNSP/ADR - ALPMY STOCK NEWS

Welcome to our dedicated page for ASTELLAS PHARMA UNSP/ADR news (Ticker: ALPMY), a resource for investors and traders seeking the latest updates and insights on ASTELLAS PHARMA UNSP/ADR stock.

Astellas Pharma Inc. is a global pharmaceutical company with operations in over 70 countries. The company focuses on creating innovative drugs to treat diseases with high unmet medical needs by emphasizing Biology and Modality. Beyond traditional pharmaceuticals, Astellas is exploring Rx+® healthcare solutions in collaboration with cutting-edge technology partners. Astellas recently opened a state-of-the-art West Coast Innovation Center in South San Francisco, enhancing its commitment to biotech innovation.

The company is actively involved in research and development, with recent advancements in cancer therapies like zolbetuximab, a monoclonal antibody targeting gastric and gastroesophageal cancers. Astellas' collaborations with Pfizer and Merck, as well as YASKAWA Electric Corporation, demonstrate its commitment to pioneering research and creating new treatment paradigms by integrating pharmaceutical and robotics technologies.

08/07/2023 09:00 AM

News

Astellas and Poseida Therapeutics Announce Strategic Investment to Support Poseida's Commitment to Redefining Cancer Cell Therapy

Rhea-AI Summary

Astellas Pharma will invest $50 million in Poseida Therapeutics, acquiring approximately 8.8% of the company. Astellas will also have exclusive negotiation rights for licensing Poseida's allogeneic CAR-T cell therapy product candidate for solid tumors. The investment aligns with Astellas' focus on immuno-oncology and its commitment to developing next-generation cancer drugs. Poseida is dedicated to advancing cancer cell therapy and gene therapy using genetic engineering technologies.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

10.63%

Tags

08/04/2023 09:24 PM

News

Iveric Bio Receives U.S. FDA Approval for IZERVAY™ (avacincaptad pegol intravitreal solution), a New Treatment for Geographic Atrophy

Rhea-AI Summary

Astellas Pharma Inc. announced that the U.S. FDA approved IZERVAY (TSE: 4503) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). IZERVAY is the only approved GA treatment with a statistically significant reduction in the rate of GA progression at the 12-month primary endpoint across two Phase 3 clinical trials. GA impacts an estimated 1.5 million people in the U.S. and can cause irreversible vision loss.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

10.63%

Tags

07/31/2023 07:30 PM

News

China's National Medical Products Administration Accepts Astellas' Biologics License Application for Zolbetuximab

Rhea-AI Summary

Astellas Pharma announced that the China National Medical Products Administration has accepted the Biologics License Application for zolbetuximab, a targeted monoclonal antibody for gastric cancer treatment in China. China accounts for nearly half of the world's new cases of gastric cancer. The BLA is based on Phase 3 clinical trials, and if approved, zolbetuximab would be the first therapy of its kind available in China.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-1.09%

Tags

07/18/2023 09:00 AM

News

Astellas and Eko Health Announce Agreement to Incorporate Next Generation Eko CORE 500™ Digital Stethoscope into Z1608, an Innovative Solution Under Development for Heart Failure Patients Built on Welldoc's Proven Digital Therapeutic Platform

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

1.24%

Tags

07/13/2023 07:30 PM

News

European Medicines Agency Accepts Astellas' Marketing Authorization Application for Zolbetuximab

Rhea-AI Summary

Astellas Pharma has announced that the European Medicines Agency (EMA) has accepted its marketing authorization application for zolbetuximab, a first-in-class investigational monoclonal antibody for the treatment of gastric cancer. If approved, zolbetuximab would be the first therapy of its kind available in Europe. Gastric cancer accounted for 3.1% of all new cancer cases in Europe in 2020, with an average five-year survival rate of 26% across all stages.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-0.76%

Tags

07/11/2023 07:00 PM

News

Astellas Completes Acquisition of Iveric Bio

Rhea-AI Summary

Astellas Pharma Inc. has completed the acquisition of IVERIC bio, Inc. Iveric Bio is now Astellas' wholly-owned subsidiary. The acquisition was completed on July 11, 2023, following all necessary approvals. Astellas aims to become a leader in the development and commercialization of treatments for retinal diseases.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-0.14%

Tags

07/10/2023 07:30 PM

News

Astellas and 4D Molecular Therapeutics (4DMT) Enter into License Agreement to Use 4DMT's Proprietary Intravitreal R100 Vector for Rare Ophthalmic Targets

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

1.04%

Tags

07/06/2023 02:00 AM

News

Astellas Announces U.S. FDA Grants Priority Review for Zolbetuximab Biologics License Application

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-0.14%

Tags

06/29/2023 12:00 AM

News

Astellas Establishes Open Innovation Hub for Tumor Microenvironment Research with Cutting-Edge Spatial Biology, in Mitsui Fudosan's "MITSUI LINK-Lab KASHIWA-NO-HA 1"

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-2.44%

Tags

06/27/2023 07:31 PM

News

Phase 3b Trial of Fezolinetant Shows Positive Topline Results for Treatment of VMS Due to Menopause

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

Tags

FAQ

What is the current stock price of ASTELLAS PHARMA UNSP/ADR (ALPMY)?

The current stock price of ASTELLAS PHARMA UNSP/ADR (ALPMY) is $9.65 as of December 24, 2024.

What is the market cap of ASTELLAS PHARMA UNSP/ADR (ALPMY)?

The market cap of ASTELLAS PHARMA UNSP/ADR (ALPMY) is approximately 18.8B.

What is Astellas Pharma Inc. known for?

Astellas Pharma Inc. is recognized as a leading global pharmaceutical company operating in over 70 countries, focusing on developing innovative drugs for diseases with high unmet medical needs.

What recent achievements has Astellas Pharma Inc. made?

Astellas recently inaugurated a modern West Coast Innovation Center in South San Francisco, enhancing its presence in the biotech ecosystem.

What is zolbetuximab, and why is it significant?

Zolbetuximab is an investigational monoclonal antibody aimed at treating gastric and gastroesophageal cancers and is a testament to Astellas' commitment to pioneering cancer therapies.

How does Astellas collaborate with other companies like Pfizer, Merck, and YASKAWA Electric Corporation?

Astellas collaborates with Pfizer, Merck, and YASKAWA Electric Corporation to advance research and development in innovative treatments through partnerships that integrate pharmaceutical and robotics technologies.

What is Astellas Pharma Inc.'s focus beyond traditional pharmaceuticals?

Astellas is exploring Rx+® healthcare solutions with cutting-edge technology partners, aiming to create innovative treatment approaches beyond traditional pharmaceuticals.